Cargando…

Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis

Apathy is commonly defined as a loss of motivation leading to a reduction in goal-directed behaviors. This multidimensional syndrome, which includes cognitive, emotional and behavioral components, is one of the most prevalent neuropsychiatric features of Parkinson’s disease (PD). It has been establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Béreau, Matthieu, Van Waes, Vincent, Servant, Mathieu, Magnin, Eloi, Tatu, Laurent, Anheim, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297386/
https://www.ncbi.nlm.nih.gov/pubmed/37371068
http://dx.doi.org/10.3390/cells12121599
_version_ 1785063871558451200
author Béreau, Matthieu
Van Waes, Vincent
Servant, Mathieu
Magnin, Eloi
Tatu, Laurent
Anheim, Mathieu
author_facet Béreau, Matthieu
Van Waes, Vincent
Servant, Mathieu
Magnin, Eloi
Tatu, Laurent
Anheim, Mathieu
author_sort Béreau, Matthieu
collection PubMed
description Apathy is commonly defined as a loss of motivation leading to a reduction in goal-directed behaviors. This multidimensional syndrome, which includes cognitive, emotional and behavioral components, is one of the most prevalent neuropsychiatric features of Parkinson’s disease (PD). It has been established that the prevalence of apathy increases as PD progresses. However, the pathophysiology and anatomic substrate of this syndrome remain unclear. Apathy seems to be underpinned by impaired anatomical structures that link the prefrontal cortex with the limbic system. It can be encountered in the prodromal stage of the disease and in fluctuating PD patients receiving bilateral chronic subthalamic nucleus stimulation. In these stages, apathy may be considered as a disorder of motivation that embodies amotivational behavioral syndrome, is underpinned by combined dopaminergic and serotonergic denervation and is dopa-responsive. In contrast, in advanced PD patients, apathy may be considered as cognitive apathy that announces cognitive decline and PD dementia, is underpinned by diffuse neurotransmitter system dysfunction and Lewy pathology spreading and is no longer dopa-responsive. In this review, we discuss the clinical patterns of apathy and their treatment, the neurobiological basis of apathy, the potential role of the anatomical structures involved and the pathways in motivational and cognitive apathy.
format Online
Article
Text
id pubmed-10297386
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102973862023-06-28 Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis Béreau, Matthieu Van Waes, Vincent Servant, Mathieu Magnin, Eloi Tatu, Laurent Anheim, Mathieu Cells Review Apathy is commonly defined as a loss of motivation leading to a reduction in goal-directed behaviors. This multidimensional syndrome, which includes cognitive, emotional and behavioral components, is one of the most prevalent neuropsychiatric features of Parkinson’s disease (PD). It has been established that the prevalence of apathy increases as PD progresses. However, the pathophysiology and anatomic substrate of this syndrome remain unclear. Apathy seems to be underpinned by impaired anatomical structures that link the prefrontal cortex with the limbic system. It can be encountered in the prodromal stage of the disease and in fluctuating PD patients receiving bilateral chronic subthalamic nucleus stimulation. In these stages, apathy may be considered as a disorder of motivation that embodies amotivational behavioral syndrome, is underpinned by combined dopaminergic and serotonergic denervation and is dopa-responsive. In contrast, in advanced PD patients, apathy may be considered as cognitive apathy that announces cognitive decline and PD dementia, is underpinned by diffuse neurotransmitter system dysfunction and Lewy pathology spreading and is no longer dopa-responsive. In this review, we discuss the clinical patterns of apathy and their treatment, the neurobiological basis of apathy, the potential role of the anatomical structures involved and the pathways in motivational and cognitive apathy. MDPI 2023-06-10 /pmc/articles/PMC10297386/ /pubmed/37371068 http://dx.doi.org/10.3390/cells12121599 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Béreau, Matthieu
Van Waes, Vincent
Servant, Mathieu
Magnin, Eloi
Tatu, Laurent
Anheim, Mathieu
Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title_full Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title_fullStr Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title_full_unstemmed Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title_short Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
title_sort apathy in parkinson’s disease: clinical patterns and neurobiological basis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297386/
https://www.ncbi.nlm.nih.gov/pubmed/37371068
http://dx.doi.org/10.3390/cells12121599
work_keys_str_mv AT bereaumatthieu apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis
AT vanwaesvincent apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis
AT servantmathieu apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis
AT magnineloi apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis
AT tatulaurent apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis
AT anheimmathieu apathyinparkinsonsdiseaseclinicalpatternsandneurobiologicalbasis